ASND:NGS-Ascendis Pharma A/S (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 142.1

Change

+1.93 (+1.38)%

Market Cap

USD 0.51B

Volume

0.25M

Analyst Target

USD 176.55
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Ascendis Pharma A/S is a biotechnology company that applies its TransCon technology to develop a pipeline of long-acting prodrug therapies with profiles that address markets with unmet medical needs.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-1.98 (-0.49%)

USD 102.73B
REGN Regeneron Pharmaceuticals Inc

+34.13 (+3.78%)

USD 96.94B
MRNA Moderna Inc

+14.13 (+12.68%)

USD 38.83B
ARGX argenx NV ADR

+10.08 (+2.63%)

USD 22.99B
BNTX BioNTech SE

+2.29 (+2.55%)

USD 21.93B
ALNY Alnylam Pharmaceuticals Inc

+0.35 (+0.23%)

USD 18.96B
GMAB Genmab AS

-1.03 (-3.58%)

USD 18.26B
RPRX Royalty Pharma Plc

+0.69 (+2.46%)

USD 16.73B
BGNE BeiGene Ltd

+5.48 (+3.50%)

USD 16.68B
BMRN Biomarin Pharmaceutical Inc

+0.47 (+0.56%)

USD 15.35B

ETFs Containing ASND

MEDI Harbor Health Care ETF 16.22 % 0.00 %

+0.22 (+0.92%)

USD 0.01B
SYNB Putnam Biorevolution ETF 3.93 % 0.00 %

+0.27 (+0.92%)

USD 5.43M
BBP Virtus LifeSci Biotech Pr.. 0.00 % 0.79 %

+0.56 (+0.92%)

USD 0.02B
FFTY Innovator IBD® 50 ETF 0.00 % 0.80 %

+0.44 (+0.92%)

USD 0.08B
MEU:CA Mackenzie Maximum Diversi.. 0.00 % 0.61 %

N/A

CAD 6.56M

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.82% 69% C- 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.82% 69% C- 80% B-
Trailing 12 Months  
Capital Gain 78.14% 87% B+ 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 78.14% 87% B+ 92% A
Trailing 5 Years  
Capital Gain 31.54% 80% B- 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.54% 79% B- 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 0.78% 60% D- 48% F
Dividend Return 0.78% 59% D- 44% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.12% 91% A- 68% D+
Risk Adjusted Return 2.98% 60% D- 43% F
Market Capitalization 0.51B 98% N/A 92% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 1.19 69% 92%
Price/Book Ratio 14.55 10% 7%
Price / Cash Flow Ratio -16.98 90% 86%
Price/Free Cash Flow Ratio -20.75 95% 90%
Management Effectiveness  
Return on Equity -818.43% 10% 4%
Return on Invested Capital -79.02% 38% 15%
Return on Assets -29.73% 51% 17%
Debt to Equity Ratio -366.68% 96% 97%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector